Skip to main content
Top
Published in: Archives of Virology 3/2016

01-03-2016 | Original Article

Association of IL28B rs8099917 genotype and female sex with spontaneous clearance of hepatitis C virus infection: a Japanese cross-sectional study

Authors: Hiroaki Ikezaki, Norihiro Furusyo, Satoshi Hiramine, Kazuya Ura, Fujiko Mitsumoto-Kaseida, Koji Takayama, Motohiro Shimizu, Kazuhiro Toyoda, Eiichi Ogawa, Mosaburo Kainuma, Masayuki Murata, Jun Hayashi

Published in: Archives of Virology | Issue 3/2016

Login to get access

Abstract

Hepatitis C virus (HCV) infection is a serious global health problem. Previous studies have suggested that the interleukin 28B (IL28B) rs8099917 genotype is related to spontaneous clearance of HCV in Caucasian populations. Our objective was to investigate the association of the IL28B rs8099917 genotype with spontaneous clearance of HCV by community-dwelling Japanese. A cross-sectional community-based population study of 993 Japanese residents was conducted. Based on anti-HCV antibody and HCV RNA levels, 50 subjects were assigned to the spontaneous-clearance group, 155 to the chronic-infection group, and 788 to the control group. Logistic regression analysis was done to examine the roles of the IL28B rs8099917 genotype and sex. To analyze the interactions between these factors, an “IL28B rs809991 genotype × sex” interaction term was included in the multivariate analysis. Significantly more subjects in the spontaneous-clearance group than in the chronic-infection group had the favorable IL28B rs8099917 genotype and were female. Multivariate logistic regression analysis extracted the favorable IL28B rs8099917 TT genotype (odds ratio [OR] 9.39; 95 % confidence interval [CI], 2.16–40.83, P = 0.003) and female sex (OR, 2.27; 95 % CI, 1.16–4.45, P = 0.017) as factors contributing to the spontaneous clearance of HCV. No significant interaction was found between the IL28B rs8099917 genotype and sex (P for interaction = 0.428). Both the favorable IL28B rs8099917 genotype and female sex were associated with the spontaneous clearance of HCV in this Japanese population.
Literature
1.
go back to reference Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST (2013) Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57:1333–1342CrossRefPubMed Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST (2013) Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57:1333–1342CrossRefPubMed
2.
go back to reference Hajarizadeh B, Grebely J, Dore GJ (2013) Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 10:553–562CrossRefPubMed Hajarizadeh B, Grebely J, Dore GJ (2013) Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 10:553–562CrossRefPubMed
3.
go back to reference Grebely J, Dore GJ (2011) What is killing people with hepatitis C virus infection? Semin Liver Dis 31:331–339CrossRefPubMed Grebely J, Dore GJ (2011) What is killing people with hepatitis C virus infection? Semin Liver Dis 31:331–339CrossRefPubMed
4.
go back to reference Hayashi J, Kishihara Y, Yamaji K, Furusyo N, Yamamoto T, Pae Y et al (1997) Hepatitis C viral quasispecies and liver damage in patients with chronic hepatitis C virus infection. Hepatology 25:697–701CrossRefPubMed Hayashi J, Kishihara Y, Yamaji K, Furusyo N, Yamamoto T, Pae Y et al (1997) Hepatitis C viral quasispecies and liver damage in patients with chronic hepatitis C virus infection. Hepatology 25:697–701CrossRefPubMed
5.
go back to reference Hayashi J, Furusyo N, Ariyama I, Sawayama Y, Etoh Y, Kashiwagi S (2000) A relationship between the evolution of hepatitis C virus variants, liver damage, and hepatocellular carcinoma in patients with hepatitis C viremia. J Infect Dis 181:1523–1527CrossRefPubMed Hayashi J, Furusyo N, Ariyama I, Sawayama Y, Etoh Y, Kashiwagi S (2000) A relationship between the evolution of hepatitis C virus variants, liver damage, and hepatocellular carcinoma in patients with hepatitis C viremia. J Infect Dis 181:1523–1527CrossRefPubMed
6.
go back to reference Hayashi J, Kishihara Y, Yamaji K, Yoshimura E, Kawakami Y, Akazawa K et al (1995) Transmission of hepatitis C virus by health care workers in a rural area of Japan. Am J Gastroenterol 90:794–799PubMed Hayashi J, Kishihara Y, Yamaji K, Yoshimura E, Kawakami Y, Akazawa K et al (1995) Transmission of hepatitis C virus by health care workers in a rural area of Japan. Am J Gastroenterol 90:794–799PubMed
7.
go back to reference Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N et al (2000) The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 284:450–456CrossRefPubMed Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N et al (2000) The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 284:450–456CrossRefPubMed
8.
go back to reference Grebely J, Page K, Sacks-Davis R, van der Loeff MS, Rice TM, Bruneau J, InC3 Study Group et al (2014) The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology 59:109–120PubMedCentralCrossRefPubMed Grebely J, Page K, Sacks-Davis R, van der Loeff MS, Rice TM, Bruneau J, InC3 Study Group et al (2014) The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology 59:109–120PubMedCentralCrossRefPubMed
9.
go back to reference Page K, Hahn JA, Evans J, Shiboski S, Lum P, Delwart E et al (2009) Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis 200:1216–1226PubMedCentralCrossRefPubMed Page K, Hahn JA, Evans J, Shiboski S, Lum P, Delwart E et al (2009) Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis 200:1216–1226PubMedCentralCrossRefPubMed
11.
go back to reference Boglione L, Cusato J, Allegra S, Cariti G, Di Perri G, D’Avolio A (2015) Role of IL28B genotyping in patients with hepatitis C virus-associated mixed cryoglobulinemia and response to PEG-IFN and ribavirin treatment. Arch Virol 160:2009–2017CrossRefPubMed Boglione L, Cusato J, Allegra S, Cariti G, Di Perri G, D’Avolio A (2015) Role of IL28B genotyping in patients with hepatitis C virus-associated mixed cryoglobulinemia and response to PEG-IFN and ribavirin treatment. Arch Virol 160:2009–2017CrossRefPubMed
12.
go back to reference Shakado S, Sakisaka S, Okanoue T, Chayama K, Izumi N, Toyoda J et al (2014) Interleukin 28B polymorphism predicts interferon plus ribavirin treatment outcome in patients with hepatitis C virus-related liver cirrhosis: a multicenter retrospective study in Japan. Hepatol Res 44:983–992CrossRefPubMed Shakado S, Sakisaka S, Okanoue T, Chayama K, Izumi N, Toyoda J et al (2014) Interleukin 28B polymorphism predicts interferon plus ribavirin treatment outcome in patients with hepatitis C virus-related liver cirrhosis: a multicenter retrospective study in Japan. Hepatol Res 44:983–992CrossRefPubMed
13.
go back to reference Furusyo N, Ogawa E, Nakamuta M, Kajiwara E, Nomura H, Dohmen K et al (2013) Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C. J Hepatol 59:205–212CrossRefPubMed Furusyo N, Ogawa E, Nakamuta M, Kajiwara E, Nomura H, Dohmen K et al (2013) Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C. J Hepatol 59:205–212CrossRefPubMed
14.
go back to reference van den Berg CH, Grady BP, Schinkel J, van de Laar T, Molenkamp R, van Houdt R et al (2011) Female sex and IL28B, a synergism for spontaneous viral clearance in hepatitis C virus (HCV) seroconverters from a community-based cohort. PLoS One 6:e27555PubMedCentralCrossRefPubMed van den Berg CH, Grady BP, Schinkel J, van de Laar T, Molenkamp R, van Houdt R et al (2011) Female sex and IL28B, a synergism for spontaneous viral clearance in hepatitis C virus (HCV) seroconverters from a community-based cohort. PLoS One 6:e27555PubMedCentralCrossRefPubMed
15.
go back to reference Clark PJ, Thompson AJ (2012) Host genomics and HCV treatment response. J Gastroenterol Hepatol 27:212–222CrossRefPubMed Clark PJ, Thompson AJ (2012) Host genomics and HCV treatment response. J Gastroenterol Hepatol 27:212–222CrossRefPubMed
16.
go back to reference Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O’Huigin C et al (2009) Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461:798–801PubMedCentralCrossRefPubMed Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O’Huigin C et al (2009) Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461:798–801PubMedCentralCrossRefPubMed
17.
go back to reference Furusyo N, Koga T, Ai M, Otokozawa S, Kohzuma T, Ikezaki H et al (2013) Plasma glycated albumin level and atherosclerosis: results from the Kyushu and Okinawa Population Study (KOPS). Int J Cardiol 167:2066–2072CrossRefPubMed Furusyo N, Koga T, Ai M, Otokozawa S, Kohzuma T, Ikezaki H et al (2013) Plasma glycated albumin level and atherosclerosis: results from the Kyushu and Okinawa Population Study (KOPS). Int J Cardiol 167:2066–2072CrossRefPubMed
18.
go back to reference Ihara T, Furusyo N, Hayashi T, Toyoda K, Murata M, Hayashi J (2013) A population-based epidemiology survey of human parvovirus B19 infection: a project of the Kyushu and Okinawa Population Study (KOPS). Arch Virol 158:2465–2472CrossRefPubMed Ihara T, Furusyo N, Hayashi T, Toyoda K, Murata M, Hayashi J (2013) A population-based epidemiology survey of human parvovirus B19 infection: a project of the Kyushu and Okinawa Population Study (KOPS). Arch Virol 158:2465–2472CrossRefPubMed
19.
go back to reference Ogawa E, Furusyo N, Toyoda K, Taniai H, Otaguro S, Kainuma M et al (2010) Excellent superiority and specificity of COBAS TaqMan HCV assay in an early viral kinetic change during pegylated interferon alpha-2b plus ribavirin treatment. BMC Gastroenterol 10:38PubMedCentralCrossRefPubMed Ogawa E, Furusyo N, Toyoda K, Taniai H, Otaguro S, Kainuma M et al (2010) Excellent superiority and specificity of COBAS TaqMan HCV assay in an early viral kinetic change during pegylated interferon alpha-2b plus ribavirin treatment. BMC Gastroenterol 10:38PubMedCentralCrossRefPubMed
20.
go back to reference Simmonds P, Alberti A, Alter HJ, Bonino F, Bradley DW, Brechot C (1994) A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 19:1321–1324CrossRefPubMed Simmonds P, Alberti A, Alter HJ, Bonino F, Bradley DW, Brechot C (1994) A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 19:1321–1324CrossRefPubMed
21.
go back to reference Ito K, Higami K, Masaki N, Sugiyama M, Mukaide M, Saito H et al (2011) The rs8099917 polymorphism, when determined by a suitable genotyping method, is a better predictor for response to pegylated alpha interferon/ribavirin therapy in Japanese patients than other single nucleotide polymorphisms associated with interleukin-28B. J Clin Microbiol 49:1853–1860PubMedCentralCrossRefPubMed Ito K, Higami K, Masaki N, Sugiyama M, Mukaide M, Saito H et al (2011) The rs8099917 polymorphism, when determined by a suitable genotyping method, is a better predictor for response to pegylated alpha interferon/ribavirin therapy in Japanese patients than other single nucleotide polymorphisms associated with interleukin-28B. J Clin Microbiol 49:1853–1860PubMedCentralCrossRefPubMed
22.
go back to reference Lyamichev V, Mast AL, Hall JG, Prudent JR, Kaiser MW, Takova T et al (1999) Polymorphism identification and quantitative detection of genomic DNA by invasive cleavage of oligonucleotide probes. Nat Biotechnol 17:292–296CrossRefPubMed Lyamichev V, Mast AL, Hall JG, Prudent JR, Kaiser MW, Takova T et al (1999) Polymorphism identification and quantitative detection of genomic DNA by invasive cleavage of oligonucleotide probes. Nat Biotechnol 17:292–296CrossRefPubMed
23.
go back to reference Zheng H, Li M, Chi B, Wu XX, Wang J, Liu DW (2015) IL28B rs12980275 variant as a predictor of sustained virologic response to pegylated-interferon and ribavirin in chronic hepatitis C patients: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 39:576–583CrossRefPubMed Zheng H, Li M, Chi B, Wu XX, Wang J, Liu DW (2015) IL28B rs12980275 variant as a predictor of sustained virologic response to pegylated-interferon and ribavirin in chronic hepatitis C patients: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 39:576–583CrossRefPubMed
24.
go back to reference Rangnekar AS, Fontana RJ (2013) IL-28B polymorphisms and the response to antiviral therapy in HCV genotype 2 and 3 varies by ethnicity: a meta-analysis. J Viral Hepat 20:377–384PubMedCentralCrossRefPubMed Rangnekar AS, Fontana RJ (2013) IL-28B polymorphisms and the response to antiviral therapy in HCV genotype 2 and 3 varies by ethnicity: a meta-analysis. J Viral Hepat 20:377–384PubMedCentralCrossRefPubMed
25.
go back to reference Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK et al (2003) IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immun 4:69–77CrossRef Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK et al (2003) IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immun 4:69–77CrossRef
26.
go back to reference Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE et al (2003) IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immun 4:63–68CrossRef Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE et al (2003) IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immun 4:63–68CrossRef
27.
go back to reference Hayashi J, Kishihara Y, Ueno K, Yamaji K, Kawakami Y, Furusyo N et al (1998) Age-related response to interferon alfa treatment in women vs men with chronic hepatitis C virus infection. Arch Intern Med 158:177–181CrossRefPubMed Hayashi J, Kishihara Y, Ueno K, Yamaji K, Kawakami Y, Furusyo N et al (1998) Age-related response to interferon alfa treatment in women vs men with chronic hepatitis C virus infection. Arch Intern Med 158:177–181CrossRefPubMed
28.
go back to reference Furusyo N, Ogawa E, Sudoh M, Murata M, Ihara T, Hayashi T et al (2012) Raloxifene hydrochloride is an adjuvant antiviral treatment of postmenopausal women with chronic hepatitis C: a randomized trial. J Hepatol 57:1186–1192CrossRefPubMed Furusyo N, Ogawa E, Sudoh M, Murata M, Ihara T, Hayashi T et al (2012) Raloxifene hydrochloride is an adjuvant antiviral treatment of postmenopausal women with chronic hepatitis C: a randomized trial. J Hepatol 57:1186–1192CrossRefPubMed
29.
go back to reference Klein SL, Jedlicka A, Pekosz A (2010) The Xs and Y of immune responses to viral vaccines. Lancet Infect Dis 10:338–349CrossRefPubMed Klein SL, Jedlicka A, Pekosz A (2010) The Xs and Y of immune responses to viral vaccines. Lancet Infect Dis 10:338–349CrossRefPubMed
30.
go back to reference Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C (2004) Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303:1529–1531CrossRefPubMed Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C (2004) Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303:1529–1531CrossRefPubMed
31.
go back to reference Berghöfer B, Frommer T, Haley G, Fink L, Bein G, Hackstein H (2006) TLR7 ligands induce higher IFN-alpha production in females. J Immun 177:2088–2096CrossRefPubMed Berghöfer B, Frommer T, Haley G, Fink L, Bein G, Hackstein H (2006) TLR7 ligands induce higher IFN-alpha production in females. J Immun 177:2088–2096CrossRefPubMed
32.
go back to reference Osterlund PI, Pietilä TE, Veckman V, Kotenko SV, Julkunen I (2007) IFN regulatory factor family members differentially regulate the expression of type III IFN (IFN-lambda) genes. J Immun 179:3434–3442CrossRefPubMed Osterlund PI, Pietilä TE, Veckman V, Kotenko SV, Julkunen I (2007) IFN regulatory factor family members differentially regulate the expression of type III IFN (IFN-lambda) genes. J Immun 179:3434–3442CrossRefPubMed
Metadata
Title
Association of IL28B rs8099917 genotype and female sex with spontaneous clearance of hepatitis C virus infection: a Japanese cross-sectional study
Authors
Hiroaki Ikezaki
Norihiro Furusyo
Satoshi Hiramine
Kazuya Ura
Fujiko Mitsumoto-Kaseida
Koji Takayama
Motohiro Shimizu
Kazuhiro Toyoda
Eiichi Ogawa
Mosaburo Kainuma
Masayuki Murata
Jun Hayashi
Publication date
01-03-2016
Publisher
Springer Vienna
Published in
Archives of Virology / Issue 3/2016
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI
https://doi.org/10.1007/s00705-015-2703-9

Other articles of this Issue 3/2016

Archives of Virology 3/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.